Novartis Reaches New 52-Week High (NVS)

NEW YORK ( TheStreet) -- Novartis (NYSE: NVS) hit a new 52-week high Tuesday as it is currently trading at $59.56, above its previous 52-week high of $59.55 with 2.3 million shares traded as of 2:30 p.m. ET. Average volume has been 1.9 million shares over the past 30 days.

Novartis has a market cap of $142.83 billion and is part of the health care sector and drugs industry. Shares are up 2.6% year to date as of the close of trading on Monday.

Novartis AG, through its subsidiaries, engages in the research, development, manufacture, and marketing of healthcare products worldwide. The company has a P/E ratio of 15.5, below the average drugs industry P/E ratio of 16.6 and below the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Novartis as a buy. The company's strengths can be seen in multiple areas, such as its attractive valuation levels, increase in net income, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. You can view the full Novartis Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.
null

If you liked this article you might like

Novartis CEO Joe Jimenez to Step Down in 2018

FDA Greenlights Novartis' Gene Therapy for Leukemia

Novartis' CAR-T Gene Therapy Receives FDA Approval

Novartis AG, Sirius XM Radio, Coupa Software: 'Mad Money' Lightning Round

August's Inexplicable Selloffs Are Here: Cramer's 'Mad Money' Recap (8/17/17)